OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer
F. Backes, J. Fowler, L. Copeland, L. Wei, D. O’Malley, D. Cohn, C. Cosgrove, J. Hays, K. Bixel
{"title":"OP007/#276 Phase I study of mirvetuximab soravtansine (MIRV) and rucaparib for recurrent endometrial, ovarian, fallopian tube or primary peritoneal cancer","authors":"F. Backes, J. Fowler, L. Copeland, L. Wei, D. O’Malley, D. Cohn, C. Cosgrove, J. Hays, K. Bixel","doi":"10.1136/ijgc-2021-igcs.24","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19598,"journal":{"name":"Oral Featured Posters","volume":"11 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Featured Posters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2021-igcs.24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
